Stage 4 Endometrial Cancer Survival Rate

Stage 4 endometrial cancer is the most advanced form of cancer of the uterine lining. It has spread beyond the pelvis or into the lining of the bladder or bowel.¹ About 1 in 5 people whose cancer has reached distant organs are alive five years after diagnosis.² That single figure blends very different situations, and the specifics of each case shape the real outlook more than the stage number alone.

What the Stage 4 Survival Numbers Actually Mean

A five-year relative survival rate compares people who have the cancer with people of the same age who don’t. So 22% means about 22 in 100 people are alive five years after diagnosis, once deaths from unrelated causes are accounted for. US cancer statistics sort cases into “distant,” “regional” and “localized” groups instead of numbered stages, and “distant” lines up mostly with stage 4. About 11% of endometrial cancers are already distant at diagnosis, so stage 4 is the less common situation.⁷

Five-year figures come from people diagnosed at least five years ago, so they don’t reflect treatments approved since, including immunotherapy added to chemotherapy. Today’s outlook may be better than the figures suggest.

Many studies report median survival instead, the point by which half of patients have died and half are still living. In studies of stage 4 disease, median survival ranges from under a year to almost three years, depending on spread and treatment.⁸⁹

A statistic can’t predict one person’s lifespan. These rates describe large groups that mix people of different ages and general health. Your oncologist can place you within the range using your tumor type and test results.

Stage 4 itself is divided into letters. Stage 4A means the cancer has grown into the inner lining of the bladder or bowel. Stage 4B means spread to distant sites, such as the lining of the belly, lungs, liver, bone or brain, or to lymph nodes in the groin. Your pathology report or your doctor’s notes will usually show the letter.

Where the Cancer Has Spread Changes the Outlook

After surgery, people whose cancer had spread only to the lining of the abdomen lived a median of 29 months, compared with 19 months when it had spread to organs.¹⁰ Spread to bone, brain or lung each predicted shorter survival than spread to the abdominal lining.¹¹ Among organ sites, brain metastases had the worst outlook, while liver, lung and bone spread all had longer survival.¹² In one group of patients whose cancer spread through the blood, lung spread meant a median of 18.5 months compared with 10.5 months for other organs.¹³

Abdominal lining spread may do better because deposits there can often be removed during surgery. Organ spread usually means the cancer traveled through the bloodstream, and that is harder to control with surgery alone.

Ask whether the spread is limited to a few spots or widespread, since that affects whether surgery is an option. Spread to a single site can sometimes be treated directly with radiation or surgery.

How Surgery Affects Survival

Debulking surgery means removing as much of the cancer as possible from the abdomen and pelvis. When surgeons leave no tumor bigger than 1 cm, median survival was about 34 months, compared with 11 months when larger tumor was left.¹⁴ People with no visible cancer left after surgery lived longer still.¹⁵ Across several studies, complete or near-complete removal cut the risk of death by more than half.¹⁶

Some people have chemotherapy first to shrink the cancer, then surgery.¹⁷ For cancer spread through the abdomen, overall survival was similar either way, about 31 vs 29 months, though the cancer stayed controlled longer with surgery first.¹⁸ In a national study, chemotherapy first was linked to better survival in the first few months but worse survival after about five months.¹⁹ Chemotherapy first may suit people too ill for major surgery right away.

Not everyone has surgery. Widespread organ spread may make removal impossible or not worthwhile, and weak overall health can make a long operation too risky. In those cases treatment relies on medicines and sometimes radiation.

If surgery is on the table, a few questions help. Will a gynecologic oncologist, a surgeon who specializes in these cancers, operate? How likely is it that all visible cancer can be removed? How long is recovery, and how does surgery fit with chemotherapy? And does starting with chemotherapy make sense in your case?

Chemotherapy as the Backbone of Treatment

Carboplatin and paclitaxel is the worldwide first-line chemotherapy for advanced endometrial cancer.²⁰ In a large trial, people on this combination lived a median of about 37 months, similar to a harsher three-drug regimen.²¹ That trial’s median looks higher than the 22% figure would suggest because trial patients were mostly fit enough for strong treatment, and the trials included stage 3 and recurrent cases alongside stage 4. Most people who start with surgery go on to have chemotherapy afterward.²²

The drugs are usually given by IV every three weeks for about six cycles. Common side effects include tiredness, hair loss, low blood counts and numb fingers or toes. Medicines or dose changes can often manage them.

Immunotherapy and Your Tumor’s Mismatch Repair Status

Your tumor will be tested for mismatch repair, which shows whether its cells can fix copying errors in their DNA. Reports may say dMMR or MSI-H (mismatch repair deficient), meaning repair is faulty, or pMMR (mismatch repair proficient), meaning repair works. Because dMMR tumors carry many mutations, the immune system can recognize them more easily once immunotherapy releases its brakes.

Adding pembrolizumab to chemotherapy cut the risk of cancer growth or death by 70% in dMMR tumors.²³ After a year, 74% were free of progression compared with 38% on chemotherapy alone.²⁴ Adding dostarlimab to chemotherapy cut the risk of death by about two-thirds in dMMR tumors.²⁵ Quality of life stayed the same or improved with dostarlimab added.²⁶

For pMMR tumors, adding dostarlimab showed a smaller trend toward longer survival.²⁷ After chemotherapy stops working, lenvatinib plus pembrolizumab raised median survival to 18 months versus 12 months.²⁸ At five years, about 17% were alive on that combination compared with 7% on chemotherapy.²⁹ Used as the very first treatment, though, that combination did not beat chemotherapy and caused more serious side effects.³⁰

Ask your oncologist whether your tumor is dMMR or pMMR, and whether immunotherapy will be added to your first chemotherapy. Ask about immune-related side effects like thyroid problems, rash or colitis, and report new diarrhea, shortness of breath or rash promptly. These trials ran only a few years, so long-term numbers are still emerging.

Tumor Type and Other Targeted Options

Uterine serous carcinoma, an aggressive type, is found at stage 3 or 4 in about half of cases.³¹ At stage 3 or 4, about 33% with serous cancer survive five years, compared with 40-50% for clear cell and high-grade endometrioid types.³² At stage 4, pure serous cancer had a median survival of 16 months compared with 32 months for mixed types.³³ Tumors labeled p53-abnormal on molecular testing tend to have the poorest outcomes, while POLE-mutated tumors do best.³⁴

Some serous tumors make too much of a protein called HER2, which a lab test can detect.³⁵ In these HER2-positive tumors, adding trastuzumab to chemotherapy raised median survival from about 24 to 30 months.³⁶ It kept the cancer controlled nearly twice as long for newly treated stage 3 or 4 cases, without added side effects.³⁷

Many endometrial tumors carry estrogen or progesterone receptors.³⁸ Low-grade receptor-positive tumors can be controlled for a long time with hormone pills, with few side effects.³⁹ That can suit people who can’t tolerate chemotherapy.

Your pathology report holds much of this. Look for the tumor type, such as endometrioid, serous, clear cell or carcinosarcoma. Grade 1 or 2 usually means slower-growing; grade 3 means faster. Results may also include p53, POLE, HER2 and hormone receptor status. Ask which of these were tested and what each means for your treatment.

Other Factors That Affect Survival

In stage 3 and 4 disease, women with diabetes lived a median of about 20 months versus 54 months without.⁴⁰ High blood pressure was also linked to shorter survival.⁴¹ Low blood protein (albumin below 3.5) was linked to about half the survival time, likely reflecting poor nutrition or overall health.⁴²

These findings don’t prove the condition itself shortened any one person’s life. Women with diabetes or low albumin may also have been older, less able to tolerate full-dose chemotherapy or major surgery, or more likely to have other illnesses, and any of these could explain part of the gap.

Where and how you’re treated also shows up. At stage 3C or 4, Black women had five-year survival of about 25% versus 43% for white women.⁴³ Being treated at a hospital that sees fewer than 5 cases a year was linked to worse survival than one with 30 or more.⁴⁴ Being uninsured or on public insurance was linked to worse survival than private insurance.⁴⁵

Some of this you can act on. Keep diabetes and blood pressure well controlled during treatment. Ask for a dietitian if you’re losing weight or not eating well. Seek a high-volume cancer center or a gynecologic oncologist, even for a second opinion. And ask the hospital’s financial counselor about insurance and assistance.

If the Cancer Comes Back or Keeps Growing

In routine care, median survival fell from about 24 months from first treatment to 13 months from third-line treatment.⁴⁶ Only about a quarter of people who start first treatment go on to a third.⁴⁷ That makes it important to get the most effective first treatment, matched to your tumor tests.

Newer drugs that deliver chemotherapy directly to cancer cells are being tested after other treatments fail.⁴⁸ In early trials, one HER2-targeted drug shrank tumors in about 59% of patients.⁴⁹

Clinical trials can give access to new drugs before approval. Ask early, since some trials require certain earlier treatments, and use sites like ClinicalTrials.gov, which list trials by location.

Some research uses blood tests that detect tumor DNA to track how well treatment is working. Detectable tumor DNA before treatment was linked to shorter survival. These tests are mostly used in research for now.

Controlling Symptoms and Quality of Life

Short courses of pelvic radiation can relieve bleeding and pain from gynecologic cancers.⁵⁰ Radiation for symptoms often takes only a few sessions. Palliative care focuses on comfort and can be given alongside cancer treatment, so ask for a referral early, not just near the end.

Report bleeding, pain, swelling or bowel changes promptly. Counseling and support groups help with the emotional side.

Planning ahead is part of good care. Talk with your team about your goals and what matters most to you, and consider an advance directive so your wishes are known. Planning ahead doesn’t mean giving up on treatment.